it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done..
harvard medical school: "cgrp: a new era for migraine treatment.".
the report was compiled by outside researchers who went into the fda�s own database of �serious adverse [medical-drug] events.�.